Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats-Reference-Cited by-同舟云学术

Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats

Published:2009-11 Issue:4 Volume:163 Page:1171-1180
ISSN:0306-4522
Container-title:Neuroscience
language:en
Short-container-title:Neuroscience

Author:

Yamamoto N.,Soghomonian J.-J.

Publisher

Elsevier BV

Subject

General Neuroscience

Reference47 articles.

1. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats;Abercrombie;Brain Res,1990

2. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease;Andersson;Neurobiol Dis,1999

3. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in Parkinsonian rats;Breysse;J Neurosci,2003

4. Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats;Carta;Eur J Neurosci,2003

5. Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment;Carta;Eur J Neurosci,2005

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathophysiological clues to therapeutic applications of glutamate mGlu5 receptor antagonists in levodopa-induced dyskinesia;European Journal of Pharmacology;2019-07

2. New approaches to discovering drugs that treat dystonia;Expert Opinion on Drug Discovery;2019-06-04

3. Glutamatergic mechanisms in l-DOPA-induced dyskinesia and therapeutic implications;Journal of Neural Transmission;2018-01-31

4. Levodopa treatment and dendritic spine pathology;Movement Disorders;2017-09-07

5. Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias;Expert Opinion on Investigational Drugs;2017-06